Yaldigo

Medicinal product

(Invented) name

Yaldigo

Active substance (s)

Mesalazinas

Strength

1600 mg

Pharmaceutical form

modifikuoto atpalaidavimo tabletės

Route (s) of administration

vartoti per burną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

A07EC02, Mesalazine

Marketing authorisation holder

Tillotts Pharma AB, Švedija

Date of authorisation

2018-02-26

Date of renewal

2022-12-29

Documents

4201 Pakuotės lapelis 2025 05 23.docx

4201 Yaldigo 1600mg tab PCS PL 2025 05 23.docx

Stage

Perregistruotas

Controlled?

No

Controlled substance type

Legal basis

10(3)

Procedure number

SE/H/1654/001/DC

Marketing authorisation procedure

Decentralizuota procedūra

Qualitative and quantitative composition

Tabletėje yra:	1 vnt.
Mesalazinas	1600 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
99060	85165	1085165	lizdinė plokštelė	N30		Receptinis	LT/1/18/4201/001	Tiekiama	-	-	No	-	-	Download
99061	85166	1085166	lizdinė plokštelė	N60		Receptinis	LT/1/18/4201/002	Netiekiama	-	-	No	-	-
99062	85167	1085167	lizdinė plokštelė	N90		Receptinis	LT/1/18/4201/003	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2022-12-29	Perregistruotas
2018-02-26	Registruotas